Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

CompletedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations (12)

Unknown

National Taiwan University Hospital-Hsinchu Branch, Hsinchu

Chang Gung Medical Foundation-Kaohsiung Branch, Kaohsiung City

Chang Gung Medical Foundation-Keelung Branch, Keelung

China Medical University Hospital, Taichung

Chung Shan Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Mackay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang Gung Medical Foundation-Linkou Branch, Taoyuan District

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY